Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Henry Reaction. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN102399165B reveals a high-yield Chloramphenicol synthesis using nitromethane, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturers.
Patent CN102060719A reveals a safer catalytic hydrogenation route for Midodrine intermediates, offering significant cost reduction in API manufacturing and enhanced supply chain reliability.
Patent CN110156645B details a streamlined 2-step asymmetric synthesis for florfenicol intermediates, drastically cutting waste and costs while ensuring high optical purity for veterinary pharmaceutical manufacturing supply chains.
Novel synthesis of chiral (R)-alpha-phenylethylamine acetate via cobalt complex. High yield Henry reaction catalyst for pharmaceutical intermediates manufacturing.
Novel chiral phosphonous bis-amino-oxazoline copper complex enables 98% yield in Henry reactions, offering reliable pharmaceutical intermediate supply.
Patent CN118530145A details a safer route for Darunavir intermediates. High purity above 98 percent ensures supply chain stability and significant cost reduction in API intermediate manufacturing processes.
Patent CN102351777A details a novel organocatalytic route for chiral oxindoles. This report analyzes the cost-effective, metal-free synthesis for pharmaceutical intermediates.
Patent CN102059145A details a novel copper-catalyzed asymmetric Henry reaction for producing high-purity (S)-octopamine and anticancer intermediates with improved cost efficiency.
Patent CN106008611B details a novel chiral cobalt complex enabling high conversion Henry reactions with simplified synthesis for reliable supply chains.
Patent CN105111086A reveals high-yield Henry reaction route. Delivers cost reduction in pharmaceutical intermediates manufacturing and supply chain reliability.
Patent CN103497082A reveals a solvent-free Henry reaction using ethanolamine-based ionic liquids, offering high yields and catalyst reusability for reliable pharma intermediate supply chains.
Patent CN111925293A details a high-purity dopamine hydrochloride synthesis using veratraldehyde, offering significant cost reduction in API manufacturing and enhanced supply chain stability.
Novel Henry reaction method ensures high purity and scalable production for pharmaceutical intermediates supply chain efficiency and cost optimization globally
Novel synthetic route for Evogliptin intermediates ensures high purity and scalable production for global pharmaceutical supply chains.
Patent CN102399161B details asymmetric catalysis for chloramphenicol. Enhances yield and purity while reducing waste for reliable antibiotic supply chains.
Novel chiral catalyst route for Eliglustat reduces costs and enhances supply chain reliability for global pharmaceutical intermediates manufacturing partners seeking high purity.
Patent CN103772213A details a room-temperature copper-catalyzed route for (2S,3S)-2-amino-octadec-1,3-diol, offering significant cost reduction and high stereoselectivity for API manufacturing.
Patent CN103906728B reveals a novel catalytic method for tertiary aminoalcohol synthesis, offering significant supply chain and cost advantages for fine chemical intermediates manufacturing.
Patent CN104529803B reveals a novel amide synthesis route using triethylenediamine. Achieve cost reduction in pharmaceutical intermediates manufacturing with high purity.
Patent CN101857547A reveals a mild PTC method for 2-nitro-1-aryl alcohol synthesis, offering high purity, scalable production, and significant cost reduction in API manufacturing.